Life Sciences

  • February 06, 2026

    HHS Refers Hims & Hers To DOJ Amid Compound Drug Fight

    U.S. Department of Health and Human Services general counsel Mike Stuart announced Friday that his office referred Hims & Hers Health Inc. to the U.S. Department of Justice for investigation, a day after Novo Nordisk A/S threatened litigation over what it called the telehealth company's "knockoff" version of its popular weight loss drug Wegovy.

  • February 06, 2026

    NJ Judge Tosses Pacira Investor Suit Over Patent Loss

    A New Jersey federal judge on Friday threw out an investor lawsuit against Pacira BioSciences Inc. after a court invalidated a patent for its key pain management drug, ruling that the pharmaceutical company was not required to disclose litigation setbacks it encountered before the final ruling.

  • February 06, 2026

    Arizona Abortion Restrictions Found Unconstitutional

    An Arizona state court permanently struck down a slew of restrictions on abortion care in the state, including an ultrasound mandate and a ban on the mailing of abortion pills, finding that the restrictions violate the right to abortion enshrined in the state's constitution.

  • February 06, 2026

    PTAB Tosses 2nd Patent On Cologuard Colon Cancer Test

    The Patent Trial and Appeal Board has found that Geneoscopy had shown that all the claims it challenged in a patent on Exact Sciences' colon cancer test Cologuard are invalid as obvious, months after the PTAB invalidated claims in a similar patent.

  • February 06, 2026

    3rd Circ. Remands J&J Unit's Libel Suit Over Talc Study

    Johnson & Johnson's talc liability unit will get another chance to pursue libel claims against a scientist over an article she wrote linking talcum power to mesothelioma, after the Third Circuit agreed to send the case back to New Jersey federal court. 

  • February 06, 2026

    TPG Hid Exactech Defects To Dodge Liability, Trust Alleges

    The settlement trust of joint implant maker Exactech filed a billion-dollar lawsuit in Delaware Chancery Court against TPG Inc., accusing the private equity firm of controlling Exactech after buying it in 2018, concealing the implants' defects, delaying product recalls and pushing the company into Chapter 11 to avoid liability.

  • February 06, 2026

    SEC Alleges Pharma Co. Misled Investors About Cancer Drug

    The U.S. Securities and Exchange Commission is suing a Kentucky pharmaceutical company for securities fraud based on claims that the company raised $4.1 million by lying to investors about the status of its cancer treatment drug.

  • February 06, 2026

    Beasley Allen Disqualified From NJ Talc Multicounty Litigation

    A New Jersey state appeals court disqualified the Beasley Allen Law Firm from representing plaintiffs in multicounty litigation over Johnson & Johnson's talc-based baby powder, ruling Friday that a former Faegre Drinker Biddle & Reath LLP lawyer's collaborative efforts with the firm's attorneys violated ethics rules.

  • February 06, 2026

    Insulet Gets $14.9M Fee Award For Trade Secret Trial Win

    A Massachusetts federal judge awarded Insulet Corp.'s attorneys almost $15 million for their $452 million jury trial victory in a trade secrets dispute that was later reduced to $59.4 million, but the fees Goodwin Procter LLP netted were significantly less than the nearly $25 million it requested.

  • February 06, 2026

    FLSA Does Not Bar Claim Waivers, Wash. Judge Says

    The Fair Labor Standards Act does not categorically bar a contract's release of an employee's claims, a Washington federal judge ruled, finding that a former pharmaceutical manufacturing company worker's severance agreement that included a general release of claims precludes his wage suit.

  • February 06, 2026

    HHS Ends 340B Drug Rebate Pilot After Legal Challenge

    The U.S. Department of Health and Human Services has ended a proposed rebate program that would have altered how hospitals receive payments for participating in the federal 340B drug discount program, which provides discounted prescription drugs for low-income Americans, after facing a lawsuit from a major hospital association.

  • February 05, 2026

    NYAG's Insider Trading Case A Power Grab, Judge Told

    The former CEO of healthcare contractor Emergent BioSolutions Inc. has removed to federal court New York Attorney General Letitia James' insider trading case against him, alleging James is trying to expand her office's power through claims that concern questions of federal law.

  • February 05, 2026

    Full Fed. Circ. Won't Rethink Heart Monitor Patent Claim Ax

    The full Federal Circuit won't rethink a panel's refusal to revive claims in a wireless heart rate monitor patent owned by Finnish sports tech company Polar Electro Oy that a lower court found were invalid.

  • February 05, 2026

    Judge Affirms Health Cos.' Sanctions For Witness Omission

    An Illinois federal judge rejected a "vague and unsupported" bid by a home healthcare company accused of violating federal kickback laws to reconsider sanctions she ordered for failing to disclose witnesses, saying the motion "wastes everyone's time" and scolding the defendants for "impugning the character and professionalism of an able magistrate judge."

  • February 05, 2026

    David Protein Gets Ingredient Supply Antitrust Claims Tossed

    A New York federal court dismissed a lawsuit from several low-calorie food producers accusing protein bar-maker David Protein of refusing to sell them a fat replacement ingredient after it purchased the ingredient's only supplier.

  • February 05, 2026

    Patent Co., AI Research Firm Join Forces In $150M Deal

    Patent monetization venture SIM IP has announced a merger valued at $150 million with artificial intelligence research firm Garden Intel, a deal the companies said would create a first-of-its-kind platform.

  • February 05, 2026

    Novo Threatens Hims & Hers With Suit Over GLP-1 'Knockoff'

    Novo Nordisk said in a Thursday announcement it plans to take legal action against Hims & Hers Health Inc. after the telehealth company revealed a "knockoff" version of Novo's popular weight loss drug Wegovy earlier in the day. 

  • February 05, 2026

    Medtronic Hit With $382M Antitrust Verdict Over Bundling

    A California federal jury on Thursday ordered Medtronic to pay nearly $382 million to business rival Applied Medical for antitrust violations, finding the medical device giant illegally used its monopoly power to crush competition in the market for a type of surgical instrument called an advanced bipolar device.

  • February 05, 2026

    Yale Health System Seeks $4.1M Coverage For Transplant

    A Liberty Mutual unit breached a stop-loss insurance policy by denying Yale University's health system $4.1 million in coverage for a plan member's bone marrow transplant, the system told a Connecticut federal court.

  • February 05, 2026

    Trump Admin Finalizes Rule Facilitating Federal Worker Firings

    The Trump administration Thursday announced a final rule to create a new category of federal workers who would have fewer job protections and be easier to fire, implementing an executive order from early last year that could affect 50,000 employees at federal agencies.

  • February 05, 2026

    Covington, Davis Polk Lead Eikon's Upsized $381M IPO

    Oncology-focused biopharmaceutical company Eikon Therapeutics began trading publicly Thursday after raising $381 million in its upsized initial public offering.

  • February 04, 2026

    Ropes Leads Hair-Loss Firm Veradermics' Upsized $256M IPO

    Hair loss drug developer Veradermics Inc. began trading Wednesday after raising $256 million in an upsized initial public offering, with Ropes & Gray LLP representing the company and Cooley LLP representing the underwriters.

  • February 04, 2026

    'Careless Or Disingenuous': Judge Rips CareFirst Rethink Bid

    A Virginia federal judge Wednesday refused to reconsider an order reversing course and throwing out key claims in CareFirst's suit against Johnson & Johnson over the immunosuppressive drug Stelara, calling CareFirst's arguments for doing so "either careless or disingenuous."

  • February 04, 2026

    Medtronic Owes $381M For Antitrust 'War Games,' Jury Told

    An attorney for Applied Medical told a California federal jury Wednesday during closing arguments in an antitrust trial against Medtronic that internal documents from the medical device giant show it played illegal "war games" against his client and should pay up to $381 million. 

  • February 04, 2026

    Fed. Circ. Leans Toward Vacating $12.7M Copyright Award

    The Federal Circuit appeared likely to vacate a $12.7 million copyright infringement award against the federal government on Wednesday, pressing attorneys for a software developer and the government to answer what instructions should be given to the claims court on remand.

Expert Analysis

  • Series

    Law School's Missed Lessons: How To Start A Law Firm

    Author Photo

    Launching and sustaining a law firm requires skills most law schools don't teach, but every lawyer should understand a few core principles that can make the leap calculated rather than reckless, says Sam Katz at Athlaw.

  • Fed. Circ. Patent Decisions In 2025: An Empirical Review

    Author Photo

    In 2025, the Federal Circuit's increased output was not enough to keep up with its ever-growing patent case load, and patent owners and applicants fared poorly overall as the court's affirmance rate fell, says Dan Bagatell at Perkins Coie.

  • Regulatory Uncertainty Ahead For Organ Transplant System

    Author Photo

    Pending court cases against a Centers for Medicare and Medicaid Services final rule that introduced a competition-centric model for assessing organ procurement organizations' performance will significantly influence the path forward for such organizations and transplant hospitals, say attorneys at Crowell & Moring.

  • Key False Claims Act Trends From The Last Year

    Author Photo

    The False Claims Act remains a powerful enforcement tool after some record verdicts and settlements in 2025, and while traditional fraud areas remain a priority, new initiatives are raising questions about its expanding application, says Veronica Nannis at Joseph Greenwald.

  • Opinion

    It's Too Soon To Remove Suicide Warnings From GLP-1 Drugs

    Author Photo

    The U.S. Food and Drug Administration's decision this month to order removal of warnings about the risk of suicidal thoughts from GLP-1 weight-loss drugs is premature — and from a safety and legal standpoint, the downside of acting too soon could be profound, says Sean Domnick at Rafferty Domnick.

  • Series

    Hosting Exchange Students Makes Me A Better Lawyer

    Author Photo

    Opening my home to foreign exchange students makes me a better lawyer not just because prioritizing visiting high schoolers forces me to hone my organization and time management skills but also because sharing the study-abroad experience with newcomers and locals reconnects me to my community, says Alison Lippa at Nicolaides Fink.

  • FDA's 2025 Enforcement Scorecard Highlights Data Focus

    Author Photo

    The U.S. Food and Drug Administration's increased enforcement activity in 2025 was driven by artificial intelligence and a focus on foreign manufacturers, necessitating proactive compliance strategies for an environment that is increasingly reliant on data, say attorneys at Reed Smith.

  • How A 1947 Tugboat Ruling May Shape Work Product In AI Era

    Author Photo

    Rapid advances in generative artificial intelligence test work-product principles first articulated in the U.S. Supreme Court’s nearly 80-year-old Hickman v. Taylor decision, as courts and ethics bodies confront whether disclosure of attorneys’ AI prompts and outputs would reveal their thought processes, say Larry Silver and Sasha Burton at Langsam Stevens.

  • Navigating Privilege Law Patchwork In Dual-Purpose Comms

    Author Photo

    Three years after the U.S. Supreme Court declined to resolve a circuit split in In re: Grand Jury, federal courts remain split as to when attorney-client privilege applies to dual-purpose legal and business communications, and understanding the fragmented landscape is essential for managing risks, say attorneys at Covington.

  • How AI Drafting Should Transform Patent Filing Strategies

    Author Photo

    As agentic artificial intelligence reduces the time and expense required to draft and file patents, companies should shift focus away from rationing drafting hours and more toward governing optionality, says Ian Schick at Paximal.

  • 5 Advertising Law Trends That Will Shape 2026

    Author Photo

    The legal landscape for advertisers will grow only more complex this year, with ongoing trends including a federal regulatory retreat, more aggressive action by the states, a focus on child privacy and expanded scrutiny of "natural" claims, say attorneys at Reed Smith.

  • Cannabis Industry Faces An Inflection Point This Year

    Author Photo

    Cannabis industry developments last year — from the passage of a new wholesale tax in Michigan, to an executive order accelerating the federal rescheduling process — presage a more mature phase of legalization this year, with hardening expectations and enforcement to come, says Alex Leonowicz at Howard & Howard.

  • Series

    Fly-Fishing Makes Me A Better Lawyer

    Author Photo

    Much like skilled attorneys, the best anglers prize preparation, presentation and patience while respecting their adversaries — both human and trout, says Rob Braverman at Braverman Greenspun.

  • 4 Ways GCs Can Manage Growing Service Of Process Volume

    Author Photo

    As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.

  • Series

    The Law Firm Merger Diaries: Forming Measurable Ties

    Author Photo

    Relationship-building should begin as early as possible in a law firm merger, as intentional pathways to bringing people together drive collaboration, positive client response, engagements and growth, says Amie Colby at Troutman.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.